US20140249184A1 - Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use - Google Patents

Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use Download PDF

Info

Publication number
US20140249184A1
US20140249184A1 US14/279,557 US201414279557A US2014249184A1 US 20140249184 A1 US20140249184 A1 US 20140249184A1 US 201414279557 A US201414279557 A US 201414279557A US 2014249184 A1 US2014249184 A1 US 2014249184A1
Authority
US
United States
Prior art keywords
implant
haloperidol
implants
patient
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/279,557
Inventor
Steven Siegel
Karen Winey
Robert H. Lenox
Raquel E. Gur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to US14/279,557 priority Critical patent/US20140249184A1/en
Publication of US20140249184A1 publication Critical patent/US20140249184A1/en
Priority to US14/681,545 priority patent/US20150209488A1/en
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reassignment THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUR, RAQUEL E., WINEY, KAREN, LENOX, ROBERT H., SIEGEL, STEVEN
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow

Definitions

  • the invention relates to surgically implantable drug delivery systems for the long-term delivery of antipsychotic drugs, and in particular haloperidol.
  • the surgically implantable drug delivery systems of the present invention comprise a biodegradable polymer, preferably a lactide-co-glycolide copolymer, and an antipsychotic drug, preferably haloperidol, fabricated into an implant via solvent casting and compression molding. As demonstrated herein, these formulations, when implanted underneath the skin, release an effective amount of the antipsychotic drug over a period of months. Also provided in the present invention are methods for producing and using these surgically implantable drug delivery systems in the treatment of patients with psychotic disorders such as schizophrenia.
  • Consequences of medication nonadherence can extend beyond the health of the patient. While the majority of people with schizophrenia do not engage in violent behavior, a subset of patients display aggression during periods of psychosis (Casper, E. S. and Regan, J. R. Can. J. Psychiatry 1993 38(10):657-61; Lindqvist, P. and Allebeck, P. Br. J. Psychiatry 1990 157:345-50; Mitchell, E. W. Med. Sci. Law 1999 39(1):23-30; Tam et al. Psychiatr. Serv. 1996 47(1):86-8).
  • Pharmacological approaches to improved adherence include improving tolerability and efficacy of antipsychotic medication (Bustillo et al. Harv. Rev. Psychiatry 1999 6(5):229-40; Kane, J. Br. J. Psychiatry Suppl. 1999 37:26-9; Kasper, S. Int. Clin. Psychopharmacol. 1998 13 Suppl 3:S71-7; Mauskopf et al. J. Clin. Psychiatry 1999 60(Suppl 19):14-9) through development of new agents and administration of monthly depot preparations of existing agents.
  • a surgically implantable preparation can last for many months, providing patients with symptomatic improvement and possibly delayed disease progression for periods of time never before possible. Additionally, in the event of unacceptable side effects, implants can be removed. This offers a degree of reversibility not presently available with depot formulations. Further, surgically implantable formulations can be employed as a safety net in combination with oral dosing to achieve adjustments as clinically indicated.
  • Surgically implantable drug delivery systems have been applied in contraception, drug addiction, chemotherapy and pain management.
  • the most widely used, NORPLANT®, (Wyeth Laboratories Inc. Philadelphia, Pa.) provides 5 years of contraception using levonorgestrel in silicon tubing, allowing for steady state diffusion of active ingredient (Woutersz, T. B. Inter. J. of Fertility 1991 3(51):51-6).
  • Silicon-based delivery systems are ideal for hormonal delivery due to picogram daily dose requirements. However, this range is not suited for antipsychotics due to slow rates of release.
  • Polymer based delivery systems release milligram range daily dosing required for antipsychotic medications.
  • the polymers used in these systems were initially used in surgical applications (Kulkarni et al. Arch. Surg. 1966 93(5):839-43), but have been modified to integrate medications to form surgically implantable or injectable formulations that release drug over weeks to months. These materials are divided into two categories, namely non-erodible and bioerodible polymers.
  • Non-erodible polymers release drug primarily by diffusion while leaving the delivery matrix in place.
  • Non-erodible ethylene vinyl acetate (EVA) is a widely used non-erodible material.
  • EVA ethylene vinyl acetate
  • Subcutaneous delivery of haloperidol has been demonstrated in rats up to 250 days using EVA (Kohler et al. Neuroscience Letter 1994 170(1):99-102). This preparation delivered steady state levels of haloperidol in vitro with physiologic effects on striatal dopamine receptor regulation.
  • Bioerodible polymers release medication by erosion of the polymer matrix and diffusion of drug through the remaining polymer matrix.
  • bioerodible polymers include, but are not limited to, high molecular weight polymers of lactic and glycolic acids, which can be used individually or in lactide-co-glycolide copolymers (PLGA).
  • Advantages of PLGA copolymers include low antigenicity and clearance of breakdown products (lactic and glycolic acid) through the Krebs cycle. These materials have been used in microspheres for injectable depot preparations of chlorpromazine (Gao et al. J. Microencapsul. 1998 15(1):75-83) and haloperidol (Cheng et al. J. Controlled Release 1998 55(2-3):203-12) and are now in clinical use with risperidone (http://www.alkermes.com/index news.html, Apr. 22, 1999). Microspheres are delivered as a suspension, and last approximately 2 weeks.
  • U.S. Pat. No. 4,883,666 teaches encapsulation of a compound for treatment of ischemic, metabolic, congenital or degenerative disorders of the central or peripheral nervous system within an implantable biocompatible polymeric device.
  • polymer implants with antipsychotics can be used to treat schizophrenia.
  • Polymer implants used in the examples of the '666 patent all comprised the non-erodible polymer ethylene vinyl acetate (EVA) and dopamine. Further, coating of the implant with a layer of EVA except for one or two holes was required for linear release.
  • EVA ethylene vinyl acetate
  • Use of bioerodible polymers in implants is suggested at col. 7, line 60 of this patent. However, no examples of implants comprising bioerodible polymers and specific therapeutic agents are taught.
  • U.S. Pat. No. 5,601,835 teaches similar formulations to those taught in U.S. Pat. No. 4,883,666. However, these formulations are implanted directly into the central nervous system. Again, no examples of implants comprising bioerodible polymers and specific therapeutic agents are taught.
  • An object of the present invention is to provide a surgically implantable drug delivery system comprising a biodegradable polymer, preferably a lactide-co-glycolide copolymer, and an antipsychotic drug, preferably haloperidol, fabricated into an implant via solvent casting and compression molding.
  • a biodegradable polymer preferably a lactide-co-glycolide copolymer
  • an antipsychotic drug preferably haloperidol
  • Another object of the present invention is to provide a method of producing surgically implantable drug delivery systems for haloperidol which comprises dissolving the haloperidol and a biodegradable polymer, preferably a lactide-co-glycolide copolymer, in an organic solvent; solvent casting the haloperidol and biodegradable polymer solution; and molding under compression the solvent cast solution into a surgical implant.
  • a biodegradable polymer preferably a lactide-co-glycolide copolymer
  • Another object of the present invention is to provide a method for treating patients with psychotic conditions and diseases which comprises surgically implanting into a patient suffering from a psychotic condition or disease a surgically implantable drug delivery system comprising a biodegradable polymer, preferably a lactide-co-glycolide copolymer, and an antipsychotic drug, preferably haloperidol, which have been fabricated into an implant via solvent casting and compression molding.
  • a biodegradable polymer preferably a lactide-co-glycolide copolymer
  • an antipsychotic drug preferably haloperidol
  • the present invention relates to a surgically implantable preparation of an antipsychotic agent such as haloperidol which provides superior treatment outcomes due to improved medication adherence.
  • the surgically implantable preparations of the present invention are designed to last for months to years, providing for symptomatic improvement as well as possibly delaying disease progression for periods of time never before possible.
  • Advantages of administration of antipsychotic drugs via the surgically implantable delivery systems of the present invention include lower dosing and steady state serum drug levels, with fewer resultant side effects. Increased bioavailability with less variation in absorption and no first pass metabolism also decrease variation in plasma levels between individuals for a given dose. These factors promote antipsychotic efficacy with reduced drug exposure and side effects.
  • the surgically implantable drug delivery systems of the present invention can be used as a low-dose safety net for relapse prevention, with variable oral dosing of typical or atypical agents for maximum treatment benefit and supplementation during exacerbations.
  • the implant in the event of unacceptable side effects, such as neuroleptic malignant syndrome, the implant can be removed, thus offering a degree of reversibility not available with depot formulations.
  • the polymer comprises polylactide or a copolymer comprising polylactide such as a lactide-co-glycolide copolymer.
  • Preferred biodegradable polymers comprise about 50 to 100% polylactide and 0 to 50% polyglycolide.
  • the copolymer and antipsychotic drug, haloperidol are fabricated into an implant via solvent casting and compression molding.
  • the individual polymers and haloperidol are dissolved in an organic solvent and solvent cast at a temperature at which the solvent evaporates for a period of time which allows for complete drying of the polymer-drug mixture.
  • haloperidol and polymers dissolved in acetone it has been found that solvent casting at a temperature of about 60° C. for approximately 72 hours evaporates all the solvent and results in a completely dry haloperidol-polymer mixture. Complete drying can be assessed by weighing the material at the beginning of solvent casting and at the end of the solvent casting to ensure that all solvent has been evaporated.
  • Haloperidol concentrations preferably range from about 20% to about 40% in the delivery system depending upon the release period. Inclusion of haloperidol in the drug delivery system actually increases the stability of the drug delivery system. Thus, the higher the concentration of haloperidol, the more extended the period of release. This increase in stability does not occur with all drugs.
  • a second phase of more rapid release occurred between 56 and 140 days (0.23 mg/day per implant), corresponding to approximately 1.1%/day.
  • haloperidol can be delivered via a 500 mg implant of the present invention comprising 40% haloperidol.
  • Implants of the present invention were also evaluated in vivo in rodents for bioactivity. These measures included behavioral testing with apomorphine stimulated locomotion in mice, and western blot analyses of D2 receptor expression following implantation in rats. For these experiments, implant compositions were developed to create a staged series of implants that release drug for 5 months. Animals treated with haloperidol implants displayed increased striatal D2 receptor expression as well as increased apomorphine stimulated locomotion.
  • mice were tested 3 weeks after receiving implants made of 75:25 PLGA alone or 75:25 PLGA with 20% haloperidol. Baseline locomotor activity was measured for twenty minutes. Animals with control implants traveled a mean of 12223 ⁇ 433 cm, while those with haloperidol containing implants traveled an average of 7664 ⁇ 450 cm. Thus, mice with haloperidol implants traveled significantly less distance that the controls (p ⁇ 0.001). Implants were then removed and all animals were allowed to recover for 48 hours. After recovery, animals received apomorphine 0.5 mg/kg i.p. twenty minutes prior to locomotor testing, which has been shown to increase locomotor activity in mice (Ninan, I. and Kulkarni, S.
  • mice that had haloperidol implants traveled more distance than control mice (p ⁇ 0.02).
  • a mean serum level of 26 ng/ml was measured in mice implanted with haloperidol-PLGA pellets one month following implantation.
  • Implants of the present invention have also been placed in monkeys. Monkeys with implants exhibited motor side effects consistent with haloperidol release within one day of implantation. Haloperidol serum levels in the monkeys were assessed at baseline and days 5, 12, 19, 27, 40 and 55 following implantation. Data are depicted in the following Table.
  • Time Number of (days) Monkeys Mean SD baseline 3 0.00 0.00 5 3 6.91 0.38 12 3 5.36 1.32 19 3 5.30 0.48 27 2 9.27 6.16 40 2 21.05 8.49 55 2 16.71 1.74
  • the surgically implantable delivery system of the present invention provides a unique means for the long term delivery of haloperidol.
  • the delivery systems of the present invention are useful in the treatment of psychotic disorders, particularly disorders such as schizophrenia where patients are oftentimes noncompliant with their medication.
  • the delivery system of the present invention can be surgically implanted into a patient, most preferably under the skin of the patient between the muscle and the dermis, in accordance with well known techniques.
  • Haloperidol released from the bioerodible implant of the present invention maintains its bioactivity and is delivered at steady state concentrations to the patients for periods of five months or more.
  • Implants of the present invention can be used alone or combined with oral supplementation of haloperidol or another antipsychotic drugs for dynamic response to optimum medication levels. Should the patient exhibit unwanted side effects to the haloperidol, the implant can be easily removed.
  • Implants were fabricated through solvent casting and compression molding. Two polymers, 75% polylactide with 25% polyglycolide (75:25 PLGA) and 85% polylactide with 15% polyglycolide (85:15 PLGA) are present in a combined system of release during a 5-month period. Each copolymer has a distinctive period of degradation, which is determined by the ratio of lactide to glycolide and the molecular weight of the resulting molecule produced. An additional polymer of 100% polylactide (PLA) was used for in vivo testing in rats. All polymers (Alkermes Inc., Cincinnati, Ohio), has an inherent viscosity of 0.66-0.8 DL/gram in chloroform and a molecular weight distribution between 120-140 kD.
  • IACUC Institutional Animal Care and Use Committee
  • mice and rats were anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.). A 1-cm incision was made in the skin on the dorsal aspect of the animal and an implant was placed between dermis and muscle. Removal of implants was performed with identical anesthesia and incision followed by implant retrieval.
  • reducing agent Invitrogen
  • Blots were then incubated overnight with anti-D2-receptor antibody, washed with TBS, and incubated with goat-anti-rabbit horseradish peroxidase conjugate (BioRad, 1:4800) for 1 hour. Blots were then incubated with chemiluminescent substrate (Pierce) for 1 minute, wrapped with plastic and exposed to autoradiographic film.
  • chemiluminescent substrate Pieris

Abstract

Surgically implantable drug delivery systems for long-term delivery of haloperidol containing a biodegradable polymer and haloperidol fabricated into the surgically implantable drug delivery systems via solvent casting and compression molding are provided. Also provided are methods for producing the surgically implantable drug delivery systems and methods for using these systems in the treatment of psychotic disorders such as schizophrenia.

Description

    INTRODUCTION
  • This application claims the benefit of priority from U.S. Provisional Patent Application Ser. No. 60/242,304, filed Oct. 20, 2001.
  • FIELD OF THE INVENTION
  • The invention relates to surgically implantable drug delivery systems for the long-term delivery of antipsychotic drugs, and in particular haloperidol. The surgically implantable drug delivery systems of the present invention comprise a biodegradable polymer, preferably a lactide-co-glycolide copolymer, and an antipsychotic drug, preferably haloperidol, fabricated into an implant via solvent casting and compression molding. As demonstrated herein, these formulations, when implanted underneath the skin, release an effective amount of the antipsychotic drug over a period of months. Also provided in the present invention are methods for producing and using these surgically implantable drug delivery systems in the treatment of patients with psychotic disorders such as schizophrenia.
  • BACKGROUND OF THE INVENTION
  • While much research regarding the treatment of schizophrenia has focused on new pharmaceutical compounds, a major correctable cause for treatment resistance remains nonadherence with prescribed medication (Fenton et al. Schizophr. Bull. 1997 23(4):637-51; Kane, J. J. Clin. Psychopharmacol. 1985 5(3 Suppl):22s-27s). Approximately 50% of patients with schizophrenia and other chronic psychotic conditions are believed to be poorly adherent with prescribed medication (Young et al. Bull. Am. Acad. Psychiatry Law 1986 14(2):105-22). A controlled study to measure adherence with a detectable marker reported that 80% of patients with schizophrenia do not take medications as prescribed (Kapur et al. Schizophr. Res. 1991 6(1):49-53). Studies of relapsed patients have reported only 30% to meet the criteria for good adherence in the months prior to admission (Bergen et al. Aust. N Z J. Psychiatry 1998 32(6):815-22; Razali et al. Acta Psychiatr. Scand. 1995 91(5):331-5).
  • Therapeutic failure secondary to nonadherence often results in deterioration in social function and more intensive interventions including rehospitalization, such that nonadherence was the most important predictor of rehospitalization in a state hospital population (Casper, E. S. and Regan, J. R. Can. J. Psychiatry 1993 38(10):657-61). Furthermore, length of stay upon rehospitalization is shorter among medication adherent patients and they are less likely to require involuntary admission (McEvoy et al. J. Nerv. Ment. Dis. 1984 172(7):412-6). Without antipsychotic treatment, 75% of patients with schizophrenia relapse within one year of first presentation, compared to 15% of treated patients (Ayuso-Gutierrez, J. L and del Rio Vega, J. M. Schizophr. Res. 1997 28(2-3):199-206; Davis, J. M. and Andriukaitis, S. J. Clin. Psychopharmacol. 1986 6(1 Suppl):2S-10S). Discontinuation of antipsychotic medication also has been disclosed to increase risk of relapse approximately 5-fold (Robinson et al. Arch. Gen. Psychiatry 1999 56(3):241-7). Similarly, a study that followed first episode patients for 2 years found relapse rates up to 90% for non-medicated patients (Ram et al. Schizophr. Bull. 1992 18:185-207). Furthermore, good adherence following discharge from the hospital can reduce recidivism from 73% to 27% within one year (Gaebel, W. and Pietzeker, A. Pharmacopsychiatry 1985 18(3):235-9).
  • Consequences of medication nonadherence can extend beyond the health of the patient. While the majority of people with schizophrenia do not engage in violent behavior, a subset of patients display aggression during periods of psychosis (Casper, E. S. and Regan, J. R. Can. J. Psychiatry 1993 38(10):657-61; Lindqvist, P. and Allebeck, P. Br. J. Psychiatry 1990 157:345-50; Mitchell, E. W. Med. Sci. Law 1999 39(1):23-30; Tam et al. Psychiatr. Serv. 1996 47(1):86-8).
  • Efforts to increase medication adherence have incorporated behavioral and psychoeducational programs, family interventions and intensive supportive services (Agarwal et al. Int. J. Soc. Psychiatry 1998 44(2):92-106; Amador, X. F. and Gorman, J. M. Psychiatric. Clin. North Am. 1998 21(1):27-42; Bustillo et al. Harv. Rev. Psychiatry 1999 6(5):229-40; Yong et al. Bull Am. Acad. Psychiatry Law 1986 14(2):105-22).
  • Pharmacological approaches to improved adherence include improving tolerability and efficacy of antipsychotic medication (Bustillo et al. Harv. Rev. Psychiatry 1999 6(5):229-40; Kane, J. Br. J. Psychiatry Suppl. 1999 37:26-9; Kasper, S. Int. Clin. Psychopharmacol. 1998 13 Suppl 3:S71-7; Mauskopf et al. J. Clin. Psychiatry 1999 60(Suppl 19):14-9) through development of new agents and administration of monthly depot preparations of existing agents.
  • Decreased rates of discontinuation were reported for a newer agent, olanzapine, than an older one (haloperidol) (Tran et al. J. Clin. Psychiatry 1997 June 58(5):205-11; Tran et al. J. Clin. Psychiatry 1997 June 58(6):275). However, newer agents have been reported to have additional side effects including weight gain, sedation, drooling, Q-T prolongation and agranulocytosis (Campbell et al. Br. J. Clin. Pharmacol. 1999 47(1):13-22; Wetterling, T. and Mussigbrodt, H. E. J. Clin. Psychopharmacol. 1999 19(4):316-21).
  • Monthly depot preparations have been reported as an effective means to decrease relapse and rehospitalization (Gerlach, J. Int. Clin. Psychopharmacol. 1995 9 Suppl 5:17-20). Treatment for noncompliant patients with depot formulations (Haldol-decanoate) is much less expensive per year than oral preparations of newer neuroleptics (risperidone; Galzer, W. M. and Ereshefsky, L. J. Clin. Psychiatry 1996 57(8):337-45). However, a 7-year study of depot medication found a significant number of patients fail to comply with monthly injections and discontinuation linked to relapse (Curson et al. Br. J. of Psychiatry 1985 146:469-74). Therefore, while depot medication improves adherence initially, many patients still become nonadherent (Weiden et al. Psychiatric Services 1995 46(10):1049-54).
  • In contrast, a surgically implantable preparation can last for many months, providing patients with symptomatic improvement and possibly delayed disease progression for periods of time never before possible. Additionally, in the event of unacceptable side effects, implants can be removed. This offers a degree of reversibility not presently available with depot formulations. Further, surgically implantable formulations can be employed as a safety net in combination with oral dosing to achieve adjustments as clinically indicated.
  • Surgically implantable drug delivery systems have been applied in contraception, drug addiction, chemotherapy and pain management. The most widely used, NORPLANT®, (Wyeth Laboratories Inc. Philadelphia, Pa.) provides 5 years of contraception using levonorgestrel in silicon tubing, allowing for steady state diffusion of active ingredient (Woutersz, T. B. Inter. J. of Fertility 1991 3(51):51-6). Silicon-based delivery systems are ideal for hormonal delivery due to picogram daily dose requirements. However, this range is not suited for antipsychotics due to slow rates of release.
  • Polymer based delivery systems release milligram range daily dosing required for antipsychotic medications. The polymers used in these systems were initially used in surgical applications (Kulkarni et al. Arch. Surg. 1966 93(5):839-43), but have been modified to integrate medications to form surgically implantable or injectable formulations that release drug over weeks to months. These materials are divided into two categories, namely non-erodible and bioerodible polymers.
  • Non-erodible polymers release drug primarily by diffusion while leaving the delivery matrix in place. Non-erodible ethylene vinyl acetate (EVA) is a widely used non-erodible material. Subcutaneous delivery of haloperidol has been demonstrated in rats up to 250 days using EVA (Kohler et al. Neuroscience Letter 1994 170(1):99-102). This preparation delivered steady state levels of haloperidol in vitro with physiologic effects on striatal dopamine receptor regulation.
  • Bioerodible polymers release medication by erosion of the polymer matrix and diffusion of drug through the remaining polymer matrix. Examples of bioerodible polymers include, but are not limited to, high molecular weight polymers of lactic and glycolic acids, which can be used individually or in lactide-co-glycolide copolymers (PLGA). Advantages of PLGA copolymers include low antigenicity and clearance of breakdown products (lactic and glycolic acid) through the Krebs cycle. These materials have been used in microspheres for injectable depot preparations of chlorpromazine (Gao et al. J. Microencapsul. 1998 15(1):75-83) and haloperidol (Cheng et al. J. Controlled Release 1998 55(2-3):203-12) and are now in clinical use with risperidone (http://www.alkermes.com/index news.html, Apr. 22, 1999). Microspheres are delivered as a suspension, and last approximately 2 weeks.
  • Various drug delivery devices comprising biodegradable polymers are disclosed generally in, for example, U.S. Pat. No. 5,665,428, U.S. Pat. No. 5,817,343, U.S. Pat. No. 5,871,778, U.S. Pat. No. 5,989,463, U.S. Pat. No. 6,004,573, U.S. Pat. No. 6,117,949, U.S. Pat. No. 6,143,314, and U.S. Pat. No. 6,201,072. These patents each contain an extensive list of possible active agents or therapeutic classes of drugs which are suggested to be deliverable via the drug delivery device.
  • In addition, U.S. Pat. No. 4,883,666 teaches encapsulation of a compound for treatment of ischemic, metabolic, congenital or degenerative disorders of the central or peripheral nervous system within an implantable biocompatible polymeric device. At col. 13, lines 51-59, it is taught that polymer implants with antipsychotics can be used to treat schizophrenia. Polymer implants used in the examples of the '666 patent all comprised the non-erodible polymer ethylene vinyl acetate (EVA) and dopamine. Further, coating of the implant with a layer of EVA except for one or two holes was required for linear release. Use of bioerodible polymers in implants is suggested at col. 7, line 60 of this patent. However, no examples of implants comprising bioerodible polymers and specific therapeutic agents are taught.
  • U.S. Pat. No. 5,601,835 teaches similar formulations to those taught in U.S. Pat. No. 4,883,666. However, these formulations are implanted directly into the central nervous system. Again, no examples of implants comprising bioerodible polymers and specific therapeutic agents are taught.
  • As shown herein, however, not all pharmaceutical agents, and more particularly antipsychotic agents, are amenable to delivery via systems comprising bioerodible polymers.
  • SUMMARY OF THE INVENTION
  • An object of the present invention is to provide a surgically implantable drug delivery system comprising a biodegradable polymer, preferably a lactide-co-glycolide copolymer, and an antipsychotic drug, preferably haloperidol, fabricated into an implant via solvent casting and compression molding.
  • Another object of the present invention is to provide a method of producing surgically implantable drug delivery systems for haloperidol which comprises dissolving the haloperidol and a biodegradable polymer, preferably a lactide-co-glycolide copolymer, in an organic solvent; solvent casting the haloperidol and biodegradable polymer solution; and molding under compression the solvent cast solution into a surgical implant.
  • Another object of the present invention is to provide a method for treating patients with psychotic conditions and diseases which comprises surgically implanting into a patient suffering from a psychotic condition or disease a surgically implantable drug delivery system comprising a biodegradable polymer, preferably a lactide-co-glycolide copolymer, and an antipsychotic drug, preferably haloperidol, which have been fabricated into an implant via solvent casting and compression molding.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to a surgically implantable preparation of an antipsychotic agent such as haloperidol which provides superior treatment outcomes due to improved medication adherence. The surgically implantable preparations of the present invention are designed to last for months to years, providing for symptomatic improvement as well as possibly delaying disease progression for periods of time never before possible. Advantages of administration of antipsychotic drugs via the surgically implantable delivery systems of the present invention include lower dosing and steady state serum drug levels, with fewer resultant side effects. Increased bioavailability with less variation in absorption and no first pass metabolism also decrease variation in plasma levels between individuals for a given dose. These factors promote antipsychotic efficacy with reduced drug exposure and side effects. Additionally, the surgically implantable drug delivery systems of the present invention can be used as a low-dose safety net for relapse prevention, with variable oral dosing of typical or atypical agents for maximum treatment benefit and supplementation during exacerbations. Finally, in the event of unacceptable side effects, such as neuroleptic malignant syndrome, the implant can be removed, thus offering a degree of reversibility not available with depot formulations.
  • Surgically implantable delivery systems for haloperidol have now been created using biodegradable polymers. In a preferred embodiment, the polymer comprises polylactide or a copolymer comprising polylactide such as a lactide-co-glycolide copolymer. Preferred biodegradable polymers comprise about 50 to 100% polylactide and 0 to 50% polyglycolide. The copolymer and antipsychotic drug, haloperidol, are fabricated into an implant via solvent casting and compression molding. In a preferred embodiment of this method, the individual polymers and haloperidol are dissolved in an organic solvent and solvent cast at a temperature at which the solvent evaporates for a period of time which allows for complete drying of the polymer-drug mixture. For example, for haloperidol and polymers dissolved in acetone, it has been found that solvent casting at a temperature of about 60° C. for approximately 72 hours evaporates all the solvent and results in a completely dry haloperidol-polymer mixture. Complete drying can be assessed by weighing the material at the beginning of solvent casting and at the end of the solvent casting to ensure that all solvent has been evaporated. Haloperidol concentrations preferably range from about 20% to about 40% in the delivery system depending upon the release period. Inclusion of haloperidol in the drug delivery system actually increases the stability of the drug delivery system. Thus, the higher the concentration of haloperidol, the more extended the period of release. This increase in stability does not occur with all drugs. In fact, other antipsychotic drugs such as thiothixene decreased stability and the period of release of the drug delivery system when drug concentrations were increased. Solvent cast material is then compression molded at a temperature and pressure which allows the polymer-drug material to flow into the mold. For example, compression molding at 80° C. and 25,000 psi (density 1.1±0.05 grams/cc) has been demonstrated to be suitable for haloperidol implants of the present invention.
  • Implants of the present invention were characterized in vitro for release kinetics. Implants comprising 75:25 PLGA with 40% haloperidol resulted in a pattern of release characterized by an initial phase of slow release (mean=0.04 mg/day for an average of 21 mg haloperidol load per implant) from 0 to 28 days. This rate corresponds to approximately 0.21%/day during the first month. A second phase of more rapid release occurred between 28 and 84 days (0.27 mg/day per implant), corresponding to approximately 1.29%/day. Implants comprising 85:15 PLGA with 40% haloperidol displayed a similar pattern of release with a phase of slow release (mean=0.05 mg/day for an average of 21 mg haloperidol load per implant) from 0 to 56 days, corresponding to approximately 0.24%/day during the first 2 months. A second phase of more rapid release occurred between 56 and 140 days (0.23 mg/day per implant), corresponding to approximately 1.1%/day. Release from a theoretical composite system of 75:25 and 85:15 PLGA, 40% haloperidol, shows an early phase from 0 to 28 days with an average of 0.14 mg/day and more rapid release between 28 to 140 days with 0.37 mg/day. Since these values result from an average drug load of approximately 42 mg, the percent released is 0.33%/day during days 0-28 and 0.88%/day during days 28-140. The value for the positive control solution (100 ng/ml) remained stable throughout the period of 140 days. Based on these release rates, a 4 month supply of haloperidol can be delivered via a 500 mg implant of the present invention comprising 40% haloperidol.
  • Implants of the present invention were also evaluated in vivo in rodents for bioactivity. These measures included behavioral testing with apomorphine stimulated locomotion in mice, and western blot analyses of D2 receptor expression following implantation in rats. For these experiments, implant compositions were developed to create a staged series of implants that release drug for 5 months. Animals treated with haloperidol implants displayed increased striatal D2 receptor expression as well as increased apomorphine stimulated locomotion.
  • In behavioral testing with apomorphine stimulated locomotion, mice were tested 3 weeks after receiving implants made of 75:25 PLGA alone or 75:25 PLGA with 20% haloperidol. Baseline locomotor activity was measured for twenty minutes. Animals with control implants traveled a mean of 12223±433 cm, while those with haloperidol containing implants traveled an average of 7664±450 cm. Thus, mice with haloperidol implants traveled significantly less distance that the controls (p<0.001). Implants were then removed and all animals were allowed to recover for 48 hours. After recovery, animals received apomorphine 0.5 mg/kg i.p. twenty minutes prior to locomotor testing, which has been shown to increase locomotor activity in mice (Ninan, I. and Kulkarni, S. K. Psychopharmacology (Berl) 1999 142(2):175-81). After apomorphine challenge, animals that had control implants traveled a mean of 4721±476 cm, while those with haloperidol containing implants traveled a mean of 8531±2536 cm. Therefore, following removal of implants and exposure to apomorphine, mice that had haloperidol implants traveled more distance than control mice (p<0.02).
  • A mean serum level of 26 ng/ml was measured in mice implanted with haloperidol-PLGA pellets one month following implantation.
  • Western blots of striatal membranes from all rats revealed a band at an apparent molecular weight of approximately 50 kD corresponding to the predicted molecular weight of the full-length D2 receptor protein (Expert Protein Analysis System, Swiss Institute of Bioinformatics, http://www.expasy.ch/; Bunzow et al. Nature 1988 336(6201):783-7). Mean optical density of bands were quantified relative to the corresponding band for haloperidol-treated rats. Results based on three blots yielded a mean±SD relative to density for haloperidol implant-treated rats of 0.90±0.07 for the 50 kD band. The mean±SD relative density for control rats was 0.64±0.02 (p=0.0002, one tail t-test). An additional band of 25 kD was also labeled, likely corresponding to the intracellular portion of the D2 receptor containing the antigenic peptide against which the antibody was raised. Quantification of the 25 kD band yielded a relative density of 0.88±0.12 for haloperidol treated animals and 0.66±0.14 for control animals (p=0.04, one tail t-test).
  • Implants of the present invention have also been placed in monkeys. Monkeys with implants exhibited motor side effects consistent with haloperidol release within one day of implantation. Haloperidol serum levels in the monkeys were assessed at baseline and days 5, 12, 19, 27, 40 and 55 following implantation. Data are depicted in the following Table.
  • Time Number of
    (days) Monkeys Mean SD
    baseline 3 0.00 0.00
    5 3 6.91 0.38
    12 3 5.36 1.32
    19 3 5.30 0.48
    27 2 9.27 6.16
    40 2 21.05 8.49
    55 2 16.71 1.74
  • Interestingly, not all pharmaceutical agents nor all antipsychotic agents are amendable to this delivery system. For example, incorporation of the antipsychotic agent thiothixene into the implant requires lowering of the molding temperature by 40° C. and causes an acceleration in degradation of the polymer as opposed to an extension of degradation time as observed with haloperidol. Further, implant comprising thiothixene degraded at room temperature without exposure to an aqueous environment within 6 months. These implants discolored to a yellow shade and liquefied. In contrast, haloperidol implants of the present invention are stable in storage for periods exceeding one year without any signs of discoloration or change in consistency. Incorporation of the anti-depressant Fluoxetine into this delivery system resulted in an implant which caused tissue necrosis in 8 out of 8 mice tested. No tissue necrosis was observed in mice with control, Navane loaded or haloperidol-loaded implants.
  • Thus, the surgically implantable delivery system of the present invention provides a unique means for the long term delivery of haloperidol.
  • The delivery systems of the present invention are useful in the treatment of psychotic disorders, particularly disorders such as schizophrenia where patients are oftentimes noncompliant with their medication. The delivery system of the present invention can be surgically implanted into a patient, most preferably under the skin of the patient between the muscle and the dermis, in accordance with well known techniques. Haloperidol released from the bioerodible implant of the present invention maintains its bioactivity and is delivered at steady state concentrations to the patients for periods of five months or more. Implants of the present invention can be used alone or combined with oral supplementation of haloperidol or another antipsychotic drugs for dynamic response to optimum medication levels. Should the patient exhibit unwanted side effects to the haloperidol, the implant can be easily removed.
  • The following nonlimiting examples are provided to further illustrate the present invention.
  • EXAMPLES Example 1 Implant Fabrication
  • Implants were fabricated through solvent casting and compression molding. Two polymers, 75% polylactide with 25% polyglycolide (75:25 PLGA) and 85% polylactide with 15% polyglycolide (85:15 PLGA) are present in a combined system of release during a 5-month period. Each copolymer has a distinctive period of degradation, which is determined by the ratio of lactide to glycolide and the molecular weight of the resulting molecule produced. An additional polymer of 100% polylactide (PLA) was used for in vivo testing in rats. All polymers (Alkermes Inc., Cincinnati, Ohio), has an inherent viscosity of 0.66-0.8 DL/gram in chloroform and a molecular weight distribution between 120-140 kD. Individual polymers and haloperidol (Sigma, St. Louis, Mo.) were dissolved in acetone and solvent case at 60° C. for 72 hours. Solvent cast material was compression molded at 80° C. and 25,000 psi (density 1.1±0.05 grams/cc).
  • Example 2 In Vitro Assay
  • Individual implants were placed in 1 liter of phosphate buffered saline (PBS), pH 7.0 at 37° C. in constant motion. Haloperidol amount was measured by GCMS (National Medical Services, Willow Grove, Pa.). Each assay included negative controls of implants made of polymer alone and a 100 ng/ml haloperidol standard to assess stability of haloperidol in solution over time.
  • Example 3 Animals
  • Implants were tested in rats (Harlan, Indianapolis, IN) (n=9) and mice (Jackson Labs, Bar Harbor, N. Mex) (n=16). All animals were housed in an AAALAC accredited animal facility at the University of Pennsylvania. Institutional Animal Care and Use Committee (IACUC) approved all protocols. Animals were maintained with a 12:12 light:dark cycle with all testing and procedures performed during the light cycle.
  • Example 4 Implantation/Removal Surgery
  • Mice and rats were anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.). A 1-cm incision was made in the skin on the dorsal aspect of the animal and an implant was placed between dermis and muscle. Removal of implants was performed with identical anesthesia and incision followed by implant retrieval.
  • Example 5 Behavioral Testing
  • Bioactivity of haloperidol implants was assessed in mice and rats. Sixteen C57b1/6 mice received implants made of 75:25 PLGA alone (n=8) or 75:25 with 20% haloperidol (n=8) to assess the effects of implants on locomotion. Following three weeks of implantation, total distance traversed was assessed over a twenty-minute period. Implants were then removed and animals allowed to recover for 48 hours prior to retesting 20 minutes after apomorphine challenge (0.5 mg/kg i.p.) (Sigma, St Louis, Mo.).
  • Example 6 Western Blot
  • Six Sprague Dawley rats received implants made of PLA with 30-40% haloperidol. Three rats received implants of PLA alone. Implants remained in all animals for three months prior to removal. Seventy-two hours after implant removal, rats were sacrificed and brains rapidly removed, dissected into four regions (cortex, hippocampus, striatum and cerebellum) then frozen in liquid nitrogen. Western blots for quantitative analysis of D2 receptor protein were performed on striatum. Three concentrations of cortex protein from a single animal (2.5, 5 and 10 μg) were run with all blots as an internal control to insure intensity of labeling was within linearity of quantitative software. Only those blots in which the density of samples was within the linear range of internal standards were used for analyses. Western blots were performed using polyclonal antibody, WR-3526, raised against amino acids 272-282 of the D2 receptor protein (Research and Diagnostic Antibodies, Berkeley, Calif.). Striata were homogenized in homogenization buffer (20 mM HEPES, 2 mM EGTA, 1 mM PMSF, 2 μM Aprotinin and 2 mM DTE), followed by a 30-second sonication. Samples were centrifuged 100,000 g for 1 hour at 4° C. Pellets were resuspended and solubilized in homogenization buffer containing 0.1% Triton X-100. Proteins were extracted on ice for 45 minutes with occasional agitation. After extraction, proteins were centrifuged at 30,000 g for 30 minutes at 4° C. Protein samples were prepared with 25% 4× NuPAGE sample buffer plus 10% reducing agent (Invitrogen) and heat shocked at 70° C. for 10 minutes. Samples were separated on a 10% precasted mini-gel at 200 volts for 50 minutes. Proteins were transferred to PVDF at 30 volts for 1 hour. Blots were blocked with 5% milk TBS (20 mM Tris, pH=7.5, 0.5 mM NaCl), then washed for 15 minutes. Blots were then incubated overnight with anti-D2-receptor antibody, washed with TBS, and incubated with goat-anti-rabbit horseradish peroxidase conjugate (BioRad, 1:4800) for 1 hour. Blots were then incubated with chemiluminescent substrate (Pierce) for 1 minute, wrapped with plastic and exposed to autoradiographic film.
  • Example 7 Quantification
  • The intensity of each band was quantified using a densitometer model 7100 and quantitative analysis software (Bio Rad, Hercules, Calif.) and expressed as a ratio to the corresponding band in rat 1 to yield a ratio of intensity (rat 1=ratio of 1). All samples were processed simultaneously on a single blot to allow for quantitative comparisons between conditions.

Claims (13)

1-10. (canceled)
11. An implant comprising: (a) a biodegradable polymer or copolymer, wherein said biodegradable polymer or copolymer comprises polylactide or lactide-co-glycolide copolymer; and (b) haloperidol at a concentration ranging from about 20% to about 40% of the mass of said implant, wherein said implant is capable of delivering a steady state concentration of haloperidol to a patient for about 5 months.
12. The implant of claim 11, wherein said haloperidol is present in an amount of about 40%.
13. The implant claim 11, wherein said haloperidol is present in an amount of about 20%.
14. The implant of claim 11, wherein the biodegradable polymer or copolymer comprises polylactide at the concentration of about 50-100% and polyglycolide at the concentration of about 0-50%.
15. The implant of claim 11, wherein said biodegradable copolymer comprises polylactide and polyglycolide in a ratio of 85:15.
16. The implant of claim 11, wherein said biodegradable copolymer comprises polylactide and polyglycolide in a ratio of 75:25.
17. The implant of claim 11, wherein said implant is surgically implantable to said patient.
18. The implant of claim 17, wherein said implant is removable from said patient in the event said patient exhibits unwanted side effects following implantation.
19. A method for producing the implant of claim 11, wherein the method comprises the step of fabricating said implant at a physical condition that allows the haloperidol-polymer material to flow into a mold for said implant.
20. A method for treating a patient suffering from a psychotic condition or disease, the method comprising surgically implanting into said patient the implant of claim 11.
21. The method of claim 20, wherein the implant is implanted under the skin of a patient between the muscle and the dermis.
22. The method of claim 20, wherein said disease is schizophrenia.
US14/279,557 2000-10-20 2014-05-16 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use Abandoned US20140249184A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/279,557 US20140249184A1 (en) 2000-10-20 2014-05-16 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use
US14/681,545 US20150209488A1 (en) 2000-10-20 2015-04-08 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24230400P 2000-10-20 2000-10-20
US10/046,504 US7666445B2 (en) 2000-10-20 2001-10-19 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US12/582,615 US8758795B2 (en) 2000-10-20 2009-10-20 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US14/279,557 US20140249184A1 (en) 2000-10-20 2014-05-16 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/582,615 Continuation US8758795B2 (en) 2000-10-20 2009-10-20 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/681,545 Continuation US20150209488A1 (en) 2000-10-20 2015-04-08 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use

Publications (1)

Publication Number Publication Date
US20140249184A1 true US20140249184A1 (en) 2014-09-04

Family

ID=26724002

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/046,504 Expired - Lifetime US7666445B2 (en) 2000-10-20 2001-10-19 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US12/582,615 Expired - Fee Related US8758795B2 (en) 2000-10-20 2009-10-20 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US14/279,557 Abandoned US20140249184A1 (en) 2000-10-20 2014-05-16 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use
US14/681,545 Abandoned US20150209488A1 (en) 2000-10-20 2015-04-08 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/046,504 Expired - Lifetime US7666445B2 (en) 2000-10-20 2001-10-19 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US12/582,615 Expired - Fee Related US8758795B2 (en) 2000-10-20 2009-10-20 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/681,545 Abandoned US20150209488A1 (en) 2000-10-20 2015-04-08 Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use

Country Status (1)

Country Link
US (4) US7666445B2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101197540B1 (en) * 2004-01-12 2012-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Long-term delivery formulations and methods of use thereof
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) * 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101283946B1 (en) 2005-07-18 2013-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Drug-containing implants and methods of use thereof
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
CN104288767A (en) 2006-04-06 2015-01-21 纽帕特公司 Implants for the treatment of dopamine associated states
WO2008130640A1 (en) * 2007-04-19 2008-10-30 Nupathe Inc. Implants for the treatment of psychiatric states
US20130344125A1 (en) * 2010-11-26 2013-12-26 Thiresen Govender Drug delivery device
CN102764229A (en) * 2012-07-24 2012-11-07 孟宪礼 Compound haloperidol subcutaneously-implanted sustained-release agent and preparation and use methods thereof
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648096A (en) * 1992-10-26 1997-07-15 Schwarz Pharma Ag Process for the production of microcapsules
US6303137B1 (en) * 1997-01-10 2001-10-16 Jenapharm Gmbh & Co. Kg Injectable implant
US6548484B1 (en) * 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US7004977B2 (en) * 1999-11-24 2006-02-28 A Enterprises, Inc. Soft tissue substitute and method of soft tissue reformation
US8221788B2 (en) * 2006-09-18 2012-07-17 Richter Gedeon Nyrt. Pharmaceutical compositions containing rosuvastatin calcium
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8741327B2 (en) * 2004-01-12 2014-06-03 The Trustees Of The University Of Pennsylvania Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
JPS58216117A (en) 1982-06-09 1983-12-15 Mitsui Toatsu Chem Inc Preparation of rod-shaped slow-releasing formed drug
DE3710175A1 (en) * 1987-02-12 1988-08-25 Hoechst Ag MULTI-PIECE IMPLANTABLE MEDICINE PREPARATION WITH LONG-TERM EFFECT
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5601835A (en) 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
JPS6471823A (en) 1987-09-12 1989-03-16 Rohto Pharma Sustained remedy for vaginal candidiasis
JP2702729B2 (en) 1988-02-24 1998-01-26 エーザイ株式会社 Sustained release implant
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
US4989463A (en) * 1990-03-02 1991-02-05 Kerr-Mcgee Chemical Corporation Sample collection shield
JPH04217914A (en) 1990-05-10 1992-08-07 Nkk Corp Production of sustained release pharmaceutical
US5629008A (en) 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
DE69327542T2 (en) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical ANTIPSYCHOTIC-CONTAINING MICROBALL FOR DELAYED RELEASE AND METHOD FOR THEIR PRODUCTION
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
CA2474701C (en) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DE19608423A1 (en) * 1996-03-05 1997-09-11 Merck Patent Gmbh Phased drug delivery implants
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
DK0959873T3 (en) * 1996-12-20 2006-07-03 Alza Corp Gel composition and methods
UA54505C2 (en) * 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Biodegradable polymers, bound by phosphates, compositions, products and pocesses for manufacturing and using thereof
HUP0001256A3 (en) * 1997-04-03 2002-12-28 Univ Johns Hopkins Med Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, method for making the same and using them
EP1001743B1 (en) * 1997-06-04 2006-02-01 Debio Recherche Pharmaceutique S.A. Implants for controlled release of pharmaceutically active principles and method for making same
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
DE19918160A1 (en) * 1999-04-22 2000-10-26 Dystar Textilfarben Gmbh & Co Reactive dye mixtures for low-salt dyeing
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
AU2001245346A1 (en) 2000-06-28 2002-01-08 Atul J. Shukla Biodegradable vehicles and delivery systems of biologically active substances
EP1317434A4 (en) * 2000-08-14 2005-06-22 Teva Pharma Preparation of risperidone
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7666445B2 (en) 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
GB0304726D0 (en) 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
ITMI20031302A1 (en) 2003-06-26 2004-12-27 Mediolanum Pharmaceuticals Ltd USE OF ETHANOL AS A PLASTICIZER TO PREPARE SUBCUTANEOUS IMPLANTS CONTAINING THERMALABLE ACTIVE PRINCIPLES DISPERSED IN A PLGA MATRIX.
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648096A (en) * 1992-10-26 1997-07-15 Schwarz Pharma Ag Process for the production of microcapsules
US6303137B1 (en) * 1997-01-10 2001-10-16 Jenapharm Gmbh & Co. Kg Injectable implant
US7004977B2 (en) * 1999-11-24 2006-02-28 A Enterprises, Inc. Soft tissue substitute and method of soft tissue reformation
US6548484B1 (en) * 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8741327B2 (en) * 2004-01-12 2014-06-03 The Trustees Of The University Of Pennsylvania Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant
US8802127B2 (en) * 2004-01-12 2014-08-12 The Trustees Of The University Of Pennsylvania Risperidone-containing PLA:PGA implants and methods of use thereof
US8221788B2 (en) * 2006-09-18 2012-07-17 Richter Gedeon Nyrt. Pharmaceutical compositions containing rosuvastatin calcium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cheng et al., "A poly(D,L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol," in Journal of Controlled Release 55 (1998) 203-212. *

Also Published As

Publication number Publication date
US8758795B2 (en) 2014-06-24
US20150209488A1 (en) 2015-07-30
US7666445B2 (en) 2010-02-23
US20020179096A1 (en) 2002-12-05
US20100104618A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
US8758795B2 (en) Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
Saltzman et al. Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems
Siegel et al. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia
JP6857214B2 (en) Sustained release composition for injection and its use for treating joint inflammation and associated pain
Brem et al. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain
US6432438B1 (en) Biodegradable vehicle and filler
ES2699692T3 (en) Deposit system comprising glatiramer acetate
US20040018238A1 (en) Biodegradable vehicles and delivery systems of biolgically active substances
US6206920B1 (en) Composition and method for forming biodegradable implants in situ and uses of these implants
RU2412693C2 (en) Delivery system
EP0881891B1 (en) Male contraceptive implant
JP2004511431A (en) Biodegradable vehicles and delivery systems containing bioactive agents
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP2011518180A (en) Methods and compositions for treating post-operative pain comprising clonidine
US20160175482A1 (en) Composition and delivery system
Wang et al. A rapid method for creating drug implants: Translating laboratory‐based methods into a scalable manufacturing process
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
Paul et al. Delivery of insulin from hydroxyapatite ceramic microspheres: preliminary in vivo studies
CZ284806B6 (en) Subcutaneous implant for ensuring of prolonged contraceptive activity and process for preparing thereof
RU2396957C2 (en) S-mirtazapine for hot flash treatment
JPH03163032A (en) Sustained release pharmaceutical for intracephalic administration
KR20120014251A (en) Compositions and methods for bioactive coatings to improve allograft incorporation
Pei et al. Application of sustained delivery microsphere of cyclosporine A for preventing posterior capsular opacification in rabbits
Major et al. Implantable drug delivery systems
Peng et al. Solvent‐free biodegradable scleral plugs providing sustained release of vancomycin, amikacin, and dexamethasone—An in vivo study

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIEGEL, STEVEN;WINEY, KAREN;LENOX, ROBERT H.;AND OTHERS;SIGNING DATES FROM 20141016 TO 20150429;REEL/FRAME:036378/0903